<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="case-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="issn">2168-8184</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus</publisher-name><publisher-loc>Palo Alto (CA)</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098790</article-id><article-id pub-id-type="doi">10.7759/cureus.82799</article-id><article-categories><subj-group subj-group-type="heading"><subject>Internal Medicine</subject></subj-group><subj-group><subject>Pulmonology</subject></subj-group><subj-group><subject>Environmental Health</subject></subj-group></article-categories><title-group><article-title>Vaping-Associated Lung Injury With Suspected Diffuse Alveolar Haemorrhage: A Case Report</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Muacevic</surname><given-names>Alexander</given-names></name></contrib><contrib contrib-type="editor"><name><surname>Adler</surname><given-names>John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Yusuf</surname><given-names>Odunayo</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Greenstreet</surname><given-names>Christian</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
Infectious Diseases, Manchester University NHS Foundation Trust, Manchester, GBR </aff><aff id="aff-2">
<label>2</label>
Acute Internal Medicine, Manchester University NHS Foundation Trust, Manchester, GBR </aff><author-notes><corresp id="cor1">
Odunayo Yusuf <email>odun99emirate@gmail.com</email>
</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>22</day><month>4</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>4</month><year>2025</year></pub-date><volume>17</volume><issue>4</issue><elocation-id>e82799</elocation-id><history><date date-type="accepted"><day>14</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025, Yusuf et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Yusuf et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xlink:href="https://www.cureus.com/articles/320874-vaping-associated-lung-injury-with-suspected-diffuse-alveolar-haemorrhage-a-case-report">This article is available from https://www.cureus.com/articles/320874-vaping-associated-lung-injury-with-suspected-diffuse-alveolar-haemorrhage-a-case-report</self-uri><abstract><p>E-cigarette or vaping product use-associated lung injury (EVALI) is a recognised condition with diverse presentations, including acute lung injury and, rarely, diffuse alveolar haemorrhage (DAH). This case report describes a rare instance of suspected DAH associated with herbal-based vape product use, highlighting diagnostic challenges and effective management.</p><p>A 44-year-old patient with Hashimoto&#x02019;s thyroiditis, asthma and six-week use of herbal or plant-based vaping solutions presented with one week of cough, fever and haemoptysis. Examination revealed respiratory distress, bilateral crackles and wheezing. Arterial blood gas showed type 1 respiratory failure (PaO&#x02082; 10.2 kPa, FiO&#x02082; 0.7), and chest imaging displayed bilateral interstitial opacities suggestive of DAH. Differentials, including pneumonia, pulmonary embolism, vasculitis, Goodpasture&#x02019;s syndrome and malignancy, were evaluated. Bronchoscopy confirmed left upper lobe haemorrhage, with bronchoalveolar lavage showing progressive red blood cells, supporting suspected DAH. Extensive autoimmune, infectious and neoplastic workup (e.g., antinuclear antibody, viral polymerase chain reaction (PCR), cultures) was negative. Empirical antibiotics and antifungals were stopped after negative cultures. On day 3, suspecting DAH, high-dose intravenous methylprednisolone (1,000 mg/day for three days) was initiated for immune-mediated inflammation, yielding rapid clinical and radiological improvement. EVALI with suspected DAH was diagnosed by exclusion post-workup, and vaping cessation was advised. At three months, the patient remained stable without recurrence.</p><p>This case underscores EVALI as a key differential in vaping patients with haemoptysis and bilateral infiltrates when other aetiologies are excluded. A thorough vaping history, comprehensive workup and prompt corticosteroid therapy can yield favourable outcomes. The rare link between DAH and EVALI warrants further research into its prevalence and management.</p></abstract><kwd-group kwd-group-type="author"><kwd>alveolar</kwd><kwd>anaemia</kwd><kwd>e-cigarette</kwd><kwd>evali</kwd><kwd>haemorrhage</kwd><kwd>lung</kwd><kwd>pulmonary</kwd><kwd>vaping</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Diffuse alveolar haemorrhage (DAH) is a rare and potentially life-threatening condition characterized by dyspnoea, haemoptysis, diffuse radiographic abnormalities and anaemia, arising from diverse aetiologies such as primary lung diseases, infections, renal or cardiac disorders and systemic autoimmune diseases [<xref rid="REF1" ref-type="bibr">1</xref>]. Immune-mediated DAH, accounting for approximately 35% of cases, is predominantly associated with ANCA-associated vasculitides, including microscopic polyangiitis and granulomatosis with polyangiitis [<xref rid="REF2" ref-type="bibr">2</xref>].</p><p>Infections, notably <italic>Staphylococcus aureus</italic> (including methicillin-resistant and Panton-Valentine leukocidin-producing strains), are less common causes but may present with haemorrhagic pneumonia, particularly in patients with acute infectious symptoms [<xref rid="REF2" ref-type="bibr">2</xref>]. DAH carries a significant in-hospital mortality rate of 24.7% [<xref rid="REF3" ref-type="bibr">3</xref>].</p><p>This case report describes a rare presentation of suspected DAH within the context of e-cigarette or vaping product use-associated lung injury (EVALI), a condition often manifesting as acute lung injury (ALI) with features like hypoxemia and bilateral infiltrates [<xref rid="REF4" ref-type="bibr">4</xref>]. Since its recognition in 2019, EVALI has been increasingly diagnosed, with early case series reporting diverse presentations, including spontaneous pneumothorax, eosinophilic pneumonia, hypersensitivity pneumonitis and, rarely, pulmonary haemorrhage [<xref rid="REF4" ref-type="bibr">4</xref>,<xref rid="REF5" ref-type="bibr">5</xref>]. Notable cases of suspected DAH linked to vaping include severe haemoptysis requiring intensive care, often associated with herbal or plant-based vape products, though confirmed cases remain sparse [<xref rid="REF6" ref-type="bibr">6</xref>,<xref rid="REF7" ref-type="bibr">7</xref>]. The overlap between suspected DAH and ALI in EVALI underscores the disease&#x02019;s heterogeneous pathology, necessitating careful diagnostic evaluation to distinguish specific patterns.</p><p>E-cigarettes, popularised since the 2000s, particularly among younger populations in Western countries, deliver aerosols containing nicotine, THC, synthetic compounds and herbal derivatives [<xref rid="REF4" ref-type="bibr">4</xref>,<xref rid="REF5" ref-type="bibr">5</xref>]. Substances such as vitamin E acetate, identified in many EVALI cases, have been shown to disrupt alveolar surfactant, induce oxidative stress and trigger proinflammatory responses, leading to epithelial and endothelial injury, capillary leakage and, in rare instances, alveolar haemorrhage [<xref rid="REF5" ref-type="bibr">5</xref>,<xref rid="REF8" ref-type="bibr">8</xref>]. These toxic effects contribute to EVALI&#x02019;s varied manifestations, including the suspected DAH observed in this case [<xref rid="REF8" ref-type="bibr">8</xref>].</p></sec><sec sec-type="cases"><title>Case presentation</title><p>A 44-year-old patient with a documented medical history of Hashimoto&#x02019;s thyroiditis and asthma presented to the emergency department with a one-week history of cough, fever and haemoptysis. The patient, a former smoker, was an active user of e-cigarettes and had transitioned, six weeks prior to presentation, to herbal or plant-based vaping solutions purchased from an online vendor. Upon clinical examination, they exhibited signs of respiratory distress, with auscultation revealing bilateral crackles and wheezing.</p><p>Arterial blood gas analysis indicated type 1 respiratory failure, with a partial pressure of oxygen (PaO&#x02082;) of 10.2 kPa on a fraction of inspired oxygen (FiO&#x02082;) of 0.7, suggesting severe hypoxemia. Laboratory findings demonstrated anaemia, mild neutrophilia and a raised&#x000a0;C-reactive protein&#x000a0;(CRP). However, eosinophil count, coagulation screen and biochemistry profile were unremarkable (Tables&#x000a0;<xref rid="TAB1" ref-type="table">1</xref>-<xref rid="TAB3" ref-type="table">3</xref>).</p><table-wrap position="float" id="TAB1"><label>Table 1</label><caption><title>Arterial blood gas analysis</title><p>BE, base excess; FiO&#x02082;, fraction of inspired oxygen; pCO&#x02082;, partial pressure of carbon dioxide; pH, potential of hydrogen; pO&#x02082;, partial pressure of oxygen</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Parameter
</td><td rowspan="1" colspan="1">
Results
</td></tr><tr><td rowspan="1" colspan="1">
FiO<sub>2</sub>
</td><td rowspan="1" colspan="1">
0.7
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
pH
</td><td rowspan="1" colspan="1">
7.42
</td></tr><tr><td rowspan="1" colspan="1">
pO<sub>2</sub>
</td><td rowspan="1" colspan="1">
10.2 kPa
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
pCO<sub>2</sub>
</td><td rowspan="1" colspan="1">
4.4 kPa
</td></tr><tr><td rowspan="1" colspan="1">
BE
</td><td rowspan="1" colspan="1">
-2
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Lactate
</td><td rowspan="1" colspan="1">
0.6 mmol/L
</td></tr><tr><td rowspan="1" colspan="1">
Bicarbonate
</td><td rowspan="1" colspan="1">
22 mmol/L
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Haemoglobin
</td><td rowspan="1" colspan="1">
69 g/L
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="TAB2"><label>Table 2</label><caption><title>Haematology: blood count and coagulation screen</title><p>APTT, activated partial thromboplastin time; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; INR, international normalised ratio; PT, prothrombin time; WBC, white blood cells</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Parameters
</td><td rowspan="1" colspan="1">
Results
</td></tr><tr><td rowspan="1" colspan="1">
Haemoglobin
</td><td rowspan="1" colspan="1">
74 g/L
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
WBC
</td><td rowspan="1" colspan="1">
10.6 &#x000d7; 10<sup>9</sup>/L
</td></tr><tr><td rowspan="1" colspan="1">
Neutrophil
</td><td rowspan="1" colspan="1">
9.7 &#x000d7; 10<sup>9</sup>/L
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Eosinophil
</td><td rowspan="1" colspan="1">
0.1 &#x000d7; 10<sup>9</sup>/L&#x000a0;
</td></tr><tr><td rowspan="1" colspan="1">
Platelet count
</td><td rowspan="1" colspan="1">
329 &#x000d7; 10<sup>9</sup>/L&#x000a0;
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
CRP
</td><td rowspan="1" colspan="1">
36 mg/L
</td></tr><tr><td rowspan="1" colspan="1">
ESR
</td><td rowspan="1" colspan="1">
18 mm/hour
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
PT
</td><td rowspan="1" colspan="1">
13.3 seconds
</td></tr><tr><td rowspan="1" colspan="1">
APTT
</td><td rowspan="1" colspan="1">
29.7 seconds
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
INR
</td><td rowspan="1" colspan="1">
1.3
</td></tr><tr><td rowspan="1" colspan="1">
Fibrinogen
</td><td rowspan="1" colspan="1">
2.9 g/L
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Lupus anticoagulant
</td><td rowspan="1" colspan="1">
Negative
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="TAB3"><label>Table 3</label><caption><title>Biochemistry profile</title></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Parameters
</td><td rowspan="1" colspan="1">
Results
</td></tr><tr><td rowspan="1" colspan="1">
Sodium
</td><td rowspan="1" colspan="1">
141 mmol/L
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Potassium
</td><td rowspan="1" colspan="1">
3.5 mmol/L
</td></tr><tr><td rowspan="1" colspan="1">
Chloride
</td><td rowspan="1" colspan="1">
107 mmol/L
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Creatinine
</td><td rowspan="1" colspan="1">
35 &#x000b5;mol/L
</td></tr><tr><td rowspan="1" colspan="1">
Urea
</td><td rowspan="1" colspan="1">
2.7 mmol/L
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Alanine aminotransferase
</td><td rowspan="1" colspan="1">
13 IU/L
</td></tr><tr><td rowspan="1" colspan="1">
Total bilirubin
</td><td rowspan="1" colspan="1">
33 &#x000b5;mol/L
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Albumin
</td><td rowspan="1" colspan="1">
37 g/L
</td></tr><tr><td rowspan="1" colspan="1">
Alkaline phosphatase
</td><td rowspan="1" colspan="1">
53 IU/L
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Calcium
</td><td rowspan="1" colspan="1">
2.21 mmol/L
</td></tr><tr><td rowspan="1" colspan="1">
Phosphate
</td><td rowspan="1" colspan="1">
1.10 mmol/L
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Magnesium
</td><td rowspan="1" colspan="1">
0.75 mmol/L
</td></tr><tr><td rowspan="1" colspan="1">
Procalcitonin
</td><td rowspan="1" colspan="1">
0.05 ng/mL
</td></tr></tbody></table></table-wrap><p>A urine dipstick test was negative for blood and protein. Initial imaging via chest radiography (Figure&#x000a0;<xref rid="FIG1" ref-type="fig">1</xref>), conducted upon admission, revealed diffuse interstitial shadowing. A subsequent CT thorax revealed extensive bilateral interstitial opacities, which the reporting radiologist noted as suggestive of possible DAH in the context of haemoptysis (Figure&#x000a0;<xref rid="FIG2" ref-type="fig">2</xref>).</p><fig position="anchor" fig-type="figure" id="FIG1"><label>Figure 1</label><caption><title>Chest X-ray on admission</title><p>Posteroanterior chest X-ray with arrows indicating bilateral diffuse opacities, predominantly involving the lower lung zones.</p></caption><graphic xlink:href="cureus-0017-00000082799-i01" position="float"/></fig><fig position="anchor" fig-type="figure" id="FIG2"><label>Figure 2</label><caption><title>Computed tomography of the thorax on admission</title><p>Axial CT thorax image showing encircled areas of bilateral interstitial ground-glass opacities.</p></caption><graphic xlink:href="cureus-0017-00000082799-i02" position="float"/></fig><p>Given the unclear aetiology underlying the patient&#x02019;s clinical presentation, a comprehensive diagnostic workup, encompassing infectious and immunological screens, was promptly initiated. Concurrently, the patient was started on an empirical treatment regimen consisting of broad-spectrum antibiotics (intravenous co-amoxiclav and clarithromycin) and an antifungal agent (voriconazole) pending infectious workup, as haemoptysis and infiltrates raised concern for infection. Potential toxicological aetiologies were also considered, prompting a detailed exploration of the patient&#x02019;s vaping history at this juncture.</p><p>By the second day of hospital admission, the patient&#x02019;s hypoxia and respiratory distress had deteriorated further. A repeat chest X-ray revealed a progression of interstitial opacities (Figure&#x000a0;<xref rid="FIG3" ref-type="fig">3</xref>). Additionally, a computed tomography pulmonary angiogram (CTPA) was conducted, effectively excluding the presence of a main stem or segmental pulmonary embolus (Figure&#x000a0;<xref rid="FIG4" ref-type="fig">4</xref>). Consequently, the patient was transferred to the intensive care unit (ICU) for enhanced monitoring and ventilatory support, as well as to facilitate bronchoscopy.</p><fig position="anchor" fig-type="figure" id="FIG3"><label>Figure 3</label><caption><title>Day 2 chest X-ray </title><p>Chest X-ray with encircled areas indicating worsening bilateral diffuse airway opacities, now involving the upper lobes compared to the admission radiograph (Figure <xref rid="FIG1" ref-type="fig">1</xref>).</p></caption><graphic xlink:href="cureus-0017-00000082799-i03" position="float"/></fig><fig position="anchor" fig-type="figure" id="FIG4"><label>Figure 4</label><caption><title>Computed axial tomography pulmonary angiogram</title><p>Encircled areas highlight the progression of interstitial ground-glass opacities observed on the initial non-contrast CT thorax (Figure&#x000a0;<xref rid="FIG2" ref-type="fig">2</xref>). No significant filling defects were identified in the bronchial or segmental pulmonary arteries to suggest pulmonary embolism.</p></caption><graphic xlink:href="cureus-0017-00000082799-i04" position="float"/></fig><p>Bedside bronchoscopy with bronchoalveolar lavage (BAL) was performed in the ICU, revealing an active haemorrhage in the left upper lobe. Analysis of three sequential BAL aliquots demonstrated a progressive increase in red blood cell content and scattered macrophages consistent with DAH suggestive of suspected DAH (as shown in the subsequent table); however, no images were recorded. Documentation regarding the evaluation of other bronchial segments was not available in the clinical records.&#x000a0;</p><p>An extensive autoimmune, oncologic and infectious disease workup, encompassing an extended respiratory viral panel, bacterial cultures, mycobacterial tuberculosis&#x000a0;polymerase chain reaction (PCR) and atypical pneumonia screens, yielded negative results (Tables&#x000a0;<xref rid="TAB4" ref-type="table">4</xref>-<xref rid="TAB6" ref-type="table">6</xref>).</p><table-wrap position="float" id="TAB4"><label>Table 4</label><caption><title>Autoimmune diagnostic evaluation of diffuse alveolar haemorrhage</title><p>ANA, anti-nuclear antibody; anti-GBM, anti-glomerular basement membrane antibody; anti-ds-DNA, double stranded-deoxyribonucleic acid; anti-MPO, anti-myeloperoxidase antibody; anti-PR3, anti-proteinase 3 antibody; RF, rheumatoid factor</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Test
</td><td rowspan="1" colspan="1">
Result
</td></tr><tr><td rowspan="1" colspan="1">
ANA
</td><td rowspan="1" colspan="1">
Negative
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Anti-ds-DNA
</td><td rowspan="1" colspan="1">
Negative
</td></tr><tr><td rowspan="1" colspan="1">
RF
</td><td rowspan="1" colspan="1">
&#x0003c;10 (0-13)
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Anti-GBM IgG
</td><td rowspan="1" colspan="1">
&#x0003c;0.2 (&#x0003c;0.9)
</td></tr><tr><td rowspan="1" colspan="1">
Anti-PR3
</td><td rowspan="1" colspan="1">
&#x0003c;0.2 (&#x0003c;0.9)
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Anti-MPO
</td><td rowspan="1" colspan="1">
&#x0003c;0.2 (&#x0003c;0.9)
</td></tr><tr><td rowspan="1" colspan="1">
PM Scl-75
</td><td rowspan="1" colspan="1">
Negative
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
PM Scl-100
</td><td rowspan="1" colspan="1">
Negative
</td></tr><tr><td rowspan="1" colspan="1">
Mi-2 alpha
</td><td rowspan="1" colspan="1">
Negative
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Mi-2 beta
</td><td rowspan="1" colspan="1">
Negative
</td></tr><tr><td rowspan="1" colspan="1">
ENA Jo-1
</td><td rowspan="1" colspan="1">
Negative
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Anti-Ro
</td><td rowspan="1" colspan="1">
Negative
</td></tr><tr><td rowspan="1" colspan="1">
Anti-La
</td><td rowspan="1" colspan="1">
Negative
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Anti-Ku
</td><td rowspan="1" colspan="1">
Negative
</td></tr><tr><td rowspan="1" colspan="1">
Anti-CN1A
</td><td rowspan="1" colspan="1">
Negative
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="TAB5"><label>Table 5</label><caption><title>Infectious diagnostic evaluation of diffuse alveolar haemorrhage</title><p>AFB, acid-fast bacilli; Abs, antibodies; BAL, bronchoalveolar lavage; COVID, coronavirus disease; ELISA, enzyme-linked immunosorbent assay; HIV, human immunodeficiency virus; IgG, immunoglobulin G; MRSA, methicillin-resistant&#x000a0;<italic>Staphylococcus aureus</italic>; PCP,&#x000a0;<italic>Pneumocystis</italic>&#x000a0;pneumonia; PCR, polymerase chain reaction; RSV, respiratory syncytial virus</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Test</td><td rowspan="1" colspan="1">Result</td></tr><tr><td rowspan="1" colspan="1">Blood cultures</td><td rowspan="1" colspan="1">Negative fungal, bacterial, AFB</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Sputum cultures</td><td rowspan="1" colspan="1">Negative fungal, bacterial, AFB</td></tr><tr><td rowspan="1" colspan="1">Urine streptococcal antigen</td><td rowspan="1" colspan="1">Negative</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Urine legionella antigen</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">Mycoplasma PCR</td><td rowspan="1" colspan="1">Negative</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">MRSA</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">HIV 1 and 2 Abs</td><td rowspan="1" colspan="1">Non-reactive</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">HIV P24 antigen</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">COVID, influenza A/B and RSV</td><td rowspan="1" colspan="1">Negative</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Extended respiratory viral PCR</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">PCP PCR (BAL)</td><td rowspan="1" colspan="1">Negative</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
<italic>Aspergillus</italic> antigen</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">
<italic>Aspergillus</italic> galactomannan Ag ELISA</td><td rowspan="1" colspan="1">Negative</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">IgG <italic>Aspergillus</italic> Ag</td><td rowspan="1" colspan="1">20 (0-40)</td></tr><tr><td rowspan="1" colspan="1">
<italic>Mycobacterium tuberculosis</italic> culture (sputum and BAL)</td><td rowspan="1" colspan="1">Negative</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Procalcitonin</td><td rowspan="1" colspan="1">0.05 ng/mL</td></tr></tbody></table></table-wrap><table-wrap position="float" id="TAB6"><label>Table 6</label><caption><title>Neoplastic diagnostic evaluation of diffuse alveolar haemorrhage</title><p>BAL, bronchoalveolar lavage; RBCs, red blood cells</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Investigation
</td><td rowspan="1" colspan="1">
Result
</td></tr><tr><td rowspan="1" colspan="1">
Peripheral blood smear
</td><td rowspan="1" colspan="1">
Negative for malignant cells
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Flow cytometry
</td><td rowspan="1" colspan="1">
Negative for malignant cells
</td></tr><tr><td rowspan="1" colspan="1">
Cytology BAL
</td><td rowspan="1" colspan="1">
RBCs predominance and scattered macrophages; no malignant cells seen
</td></tr></tbody></table></table-wrap><p>On the third day of admission, given the bronchoscopy findings and the suspicion of DAH based on haemoptysis, bronchoscopic left upper lobe haemorrhage and BAL findings (Table&#x000a0;<xref rid="TAB7" ref-type="table">7</xref>), with lack of clinical improvement despite antimicrobial therapy and largely negative initial infectious workup suggesting a non-infectious cause, the patient was commenced on a three-day course of intravenous methylprednisolone at a dosage of 1,000 mg daily, followed by a tapering regimen of oral prednisolone targeting a presumed immune-mediated or inflammatory process. With an infectious aetiology largely excluded at this point, initiation of immunosuppressive therapy with corticosteroids was considered appropriate while awaiting the results of a comprehensive immunologic workup.&#x000a0;</p><table-wrap position="float" id="TAB7"><label>Table 7</label><caption><title>Bronchoscopy and bronchoalveolar lavage (BAL) findings</title></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Parameter</td><td rowspan="1" colspan="1">Result</td></tr><tr><td rowspan="1" colspan="1">Bronchoscopy</td><td rowspan="1" colspan="1">Active haemorrhage in the left upper lobe; other segments not documented</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">BAL aliquot 1</td><td rowspan="1" colspan="1">Red blood cells present, scattered macrophages</td></tr><tr><td rowspan="1" colspan="1">BAL aliquot 2</td><td rowspan="1" colspan="1">Increased red blood cell content</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">BAL aliquot 3</td><td rowspan="1" colspan="1">Further increase in red blood cell content</td></tr><tr><td rowspan="1" colspan="1">Hemosiderin-laden macrophages</td><td rowspan="1" colspan="1">None reported</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Cytology</td><td rowspan="1" colspan="1">No malignant cells</td></tr></tbody></table></table-wrap><p>Subsequently, the patient exhibited both clinical and radiological improvement (Figure&#x000a0;<xref rid="FIG5" ref-type="fig">5</xref>). This rapid response to corticosteroids, alongside negative infectious results, supported an inflammatory process, prompting further evaluation for EVALI. In the absence of positive culture results, antibiotic and antifungal therapies were discontinued, and the patient&#x02019;s care was transitioned to the medical high-dependency unit.&#x000a0;</p><fig position="anchor" fig-type="figure" id="FIG5"><label>Figure 5</label><caption><title>Day 5 chest X-ray </title><p>This radiograph shows improving bilateral airway opacities, with arrows highlighting areas of notable change compared to imaging performed three days earlier (Figure <xref rid="FIG3" ref-type="fig">3</xref>).</p></caption><graphic xlink:href="cureus-0017-00000082799-i05" position="float"/></fig><p>The patient&#x02019;s swift clinical and radiological improvement following empiric corticosteroids, combined with negative immunological and infectious investigations (Tables&#x000a0;<xref rid="TAB4" ref-type="table">4</xref>-<xref rid="TAB5" ref-type="table">5</xref>), confirmed an underlying inflammatory process. Following multidisciplinary consultations with specialists in respiratory medicine, rheumatology and microbiology, and given the absence of definitive immunological or infectious findings, the patient was diagnosed with EVALI, characterised by suspected DAH. The suspicion of DAH, initially raised on day 3 by haemoptysis, bronchoscopic identification of left upper lobe haemorrhage, and BAL showing a progressive increase in red blood cells (Table&#x000a0;<xref rid="TAB7" ref-type="table">7</xref>), was supported by the exclusion of other causes, while concurrent type 1 respiratory failure and bilateral interstitial opacities were consistent with the ALI pattern frequently observed in EVALI, enabling clinicians to recognise similar presentations [<xref rid="REF6" ref-type="bibr">6</xref>].</p><p>The patient received comprehensive counselling on the diagnosis, with strong recommendations to permanently discontinue e-cigarette use, and was discharged with clear guidance to avoid vaping. At the three-month follow-up, the patient remained clinically stable, reporting no recurrence of symptoms.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>The diagnosis of DAH typically represents a diagnostic challenge in acute type 1 respiratory failure, with over a hundred causes previously described. The diagnostic evaluation requires prompt identification of the underlying aetiology and institution of targeted therapy [<xref rid="REF2" ref-type="bibr">2</xref>,<xref rid="REF5" ref-type="bibr">5</xref>]. The most common aetiologies include immune-related conditions, cardiac failure and a wide range of infections. Consequently, the diagnostic workup is typically extensive and comprehensive [<xref rid="REF2" ref-type="bibr">2</xref>].</p><p>This case underscores the diagnostic complexity of EVALI, particularly in distinguishing between ALI and DAH as manifestations of the disease. EVALI typically presents with ALI-like features, including acute hypoxemic respiratory failure, bilateral pulmonary infiltrates and non-cardiogenic pulmonary oedema, resembling the clinical criteria for ALI or acute respiratory distress syndrome (ARDS) [<xref rid="REF8" ref-type="bibr">8</xref>,<xref rid="REF9" ref-type="bibr">9</xref>]. However, DAH is characterised by alveolar bleeding, haemoptysis and progressive red blood cell accumulation in BAL and is a rarer but documented pattern within EVALI&#x02019;s heterogeneous spectrum [<xref rid="REF6" ref-type="bibr">6</xref>,<xref rid="REF10" ref-type="bibr">10</xref>]. In the present case, the patient&#x02019;s haemoptysis, bronchoscopic evidence of left upper lobe haemorrhage and BAL findings suggestive of alveolar bleeding prompted suspicion of DAH, yet the concurrent hypoxemia and bilateral infiltrates align with ALI&#x02019;s broader phenotype. This overlap reflects EVALI&#x02019;s variable pathology, where DAH may coexist with or mimic ALI, necessitating careful clinical correlation to guide diagnosis and management [<xref rid="REF6" ref-type="bibr">6</xref>].</p><p>EVALI manifests as a diverse spectrum of pneumonitis patterns, including eosinophilic pneumonia, organising pneumonia, hypersensitivity pneumonitis, lipoid pneumonia and, less commonly, DAH [<xref rid="REF11" ref-type="bibr">11</xref>]. Histologically, the most characteristic feature is the presence of lipid-laden pulmonary alveolar macrophages, often with vacuolisation, accompanied by vacuolated pneumocytes, findings indicative of chemical-induced pneumonitis [<xref rid="REF11" ref-type="bibr">11</xref>].</p><p>These findings are non-specific and may arise from various causes, including drugs, irritative inhalants, gastric acid aspiration and viral infections. Consequently, obtaining a thorough history, considering the clinical context and excluding other potential etiologic conditions with similar presentations are crucial [<xref rid="REF11" ref-type="bibr">11</xref>,<xref rid="REF12" ref-type="bibr">12</xref>].</p><p>This case report highlights a rare presentation of suspected DAH associated with vaping product use, ultimately diagnosed as EVALI by exclusion. However, as with all case reports, the findings are inherently limited in scope and may not be generalisable to broader populations. The patient&#x02019;s unique profile, including the use of plant-based vaping solutions, underlying asthma and rapid steroid response, represents a specific scenario that may not typify EVALI or vaping-related DAH. The rarity of DAH as a manifestation of EVALI, combined with the heterogeneity of vaping exposures, underscores the need for larger cohort studies or case series to establish its prevalence, risk factors and long-term outcomes. Such research is essential to clarify the spectrum of vaping-related lung injuries and inform standardised management strategies.</p><p>The high prevalence of THC, vitamin E acetate and various flavouring agents has yet to be fully substantiated, and further research is needed to identify the common toxic element [<xref rid="REF12" ref-type="bibr">12</xref>]. Most commercially available e-cigarette solvents are mixed with a base of vegetable glycerine, a highly lipid-soluble substance. This increases the likelihood of inflammatory substances and solvents reaching the lung parenchyma, where they can induce damage. These substances elicit inflammation of the pulmonary epithelium and endothelium, leading to collagen deposition, capillary leakage and haemorrhage [<xref rid="REF13" ref-type="bibr">13</xref>].</p><p>Management of EVALI, whether presenting as ALI or suspected DAH, relies on cessation of vaping and corticosteroid therapy tailored to the severity and suspected pathology [<xref rid="REF14" ref-type="bibr">14</xref>,<xref rid="REF15" ref-type="bibr">15</xref>]. For ALI-predominant EVALI, moderate-dose corticosteroids (e.g., prednisone 0.5-1 mg/kg/day) are typically employed to mitigate inflammation, often with supplemental oxygen or ventilatory support as required [<xref rid="REF14" ref-type="bibr">14</xref>]. In contrast, suspected DAH may necessitate high-dose pulse corticosteroids (e.g., intravenous methylprednisolone 1,000 mg/day for three days), as administered in this case, to control alveolar bleeding, followed by an oral taper [<xref rid="REF15" ref-type="bibr">15</xref>]. Prognostically, EVALI with ALI features often resolves fully with early intervention, though some patients experience persistent lung function deficits or interstitial lung disease [<xref rid="REF14" ref-type="bibr">14</xref>]. DAH in EVALI, while less studied, appears to carry a favourable prognosis with prompt treatment and vaping cessation, as evidenced by this patient&#x02019;s stability at three-month follow-up; however, untreated DAH risks severe hypoxemia or fibrosis, necessitating ongoing surveillance [<xref rid="REF15" ref-type="bibr">15</xref>].</p><p>As there is no specific treatment for EVALI, the CDC recommends cessation of e-cigarette use and corticosteroid treatment, although no standard dose is advised [<xref rid="REF16" ref-type="bibr">16</xref>]. Prognosis following steroid treatment varies significantly, ranging from complete resolution of clinical symptoms and radiographic abnormalities to the persistence of pulmonary disease, such as interstitial lung disease [<xref rid="REF4" ref-type="bibr">4</xref>,<xref rid="REF16" ref-type="bibr">16</xref>].</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>The global rise in e-cigarette use, particularly among young individuals, has brought increased attention to EVALI, a heterogeneous condition that includes ALI and rare manifestations such as suspected DAH. This case highlights the importance of considering EVALI in patients with a history of vaping who present with haemoptysis and bilateral infiltrates, especially when other causes have been ruled out.</p><p>A detailed history, including the use of plant-based vaping products, is essential due to the non-specific nature of clinical and BAL findings. Early recognition, cessation of vaping and corticosteroid therapy can lead to favourable outcomes, though further research is needed to fully understand the spectrum of EVALI and guide optimal treatment strategies.</p></sec></body><back><ack><p>Odunayo Yusuf and Christian Greenstreet contributed equally to this work and should be considered co-first authors. We would like to acknowledge the valuable contribution and guidance of Dr. Diana Chiu (Consultant Acute Physician, Salford Royal NHS Hospital), which was vital to the success of this case report. Finally, we acknowledge the use of ChatGPT Plus, which was employed solely to help ensure that no grammatical errors were overlooked.</p></ack><fn-group content-type="conflict"><title>Disclosures</title><fn fn-type="COI-statement"><p><bold>Human subjects:</bold> Consent for treatment and open access publication was obtained or waived by all participants in this study.</p><p><bold>Conflicts of interest:</bold> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p><p><bold>Payment/services info:</bold> All authors have declared that no financial support was received from any organization for the submitted work.</p><p><bold>Financial relationships:</bold> All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.</p><p><bold>Other relationships:</bold> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p></fn></fn-group><fn-group content-type="other"><title>Author Contributions</title><fn fn-type="other"><p><bold>Concept and design:</bold>&#x000a0; Odunayo Yusuf, Christian Greenstreet</p><p><bold>Acquisition, analysis, or interpretation of data:</bold>&#x000a0; Odunayo Yusuf, Christian Greenstreet</p><p><bold>Drafting of the manuscript:</bold>&#x000a0; Odunayo Yusuf, Christian Greenstreet</p><p><bold>Critical review of the manuscript for important intellectual content:</bold>&#x000a0; Odunayo Yusuf, Christian Greenstreet</p><p><bold>Supervision:</bold>&#x000a0; Christian Greenstreet</p></fn></fn-group><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="journal"><article-title>Idiopathic pulmonary hemosiderosis in a 9-year-old girl</article-title><source>Eur J Med Res</source><person-group>
<name><surname>Kamienska</surname><given-names>E</given-names></name>
<name><surname>Urasinski</surname><given-names>T</given-names></name>
<name><surname>Gawlikowska-Sroka</surname><given-names>A</given-names></name>
<name><surname>Glura</surname><given-names>B</given-names></name>
<name><surname>Pogorzelski</surname><given-names>A</given-names></name>
</person-group><fpage>112</fpage><lpage>115</lpage><volume>14 Suppl 4</volume><year>2009</year><pub-id pub-id-type="pmid">20156739</pub-id>
</element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>Diffuse alveolar hemorrhage in immunocompetent patients: etiologies and prognosis revisited</article-title><source>Respir Med</source><person-group>
<name><surname>de Prost</surname><given-names>N</given-names></name>
<name><surname>Parrot</surname><given-names>A</given-names></name>
<name><surname>Cuquemelle</surname><given-names>E</given-names></name>
<etal/>
</person-group><fpage>1021</fpage><lpage>1032</lpage><volume>106</volume><year>2012</year><pub-id pub-id-type="pmid">22541718</pub-id>
</element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>Diffuse alveolar haemorrhage: factors associated with in-hospital and long-term mortality</article-title><source>Eur Respir J</source><person-group>
<name><surname>de Prost</surname><given-names>N</given-names></name>
<name><surname>Parrot</surname><given-names>A</given-names></name>
<name><surname>Picard</surname><given-names>C</given-names></name>
<name><surname>Ancel</surname><given-names>PY</given-names></name>
<name><surname>Mayaud</surname><given-names>C</given-names></name>
<name><surname>Fartoukh</surname><given-names>M</given-names></name>
<name><surname>Cadranel</surname><given-names>J</given-names></name>
</person-group><fpage>1303</fpage><lpage>1311</lpage><volume>35</volume><year>2010</year><pub-id pub-id-type="pmid">19840965</pub-id>
</element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>E-cigarette, or vaping, product use associated lung injury (EVALI): case series and diagnostic approach</article-title><source>Lancet Respir Med</source><person-group>
<name><surname>Kalininskiy</surname><given-names>A</given-names></name>
<name><surname>Bach</surname><given-names>CT</given-names></name>
<name><surname>Nacca</surname><given-names>NE</given-names></name>
<etal/>
</person-group><fpage>1017</fpage><lpage>1026</lpage><volume>7</volume><year>2019</year><pub-id pub-id-type="pmid">31711871</pub-id>
</element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>Inhalation toxicology of vaping products and implications for pulmonary health</article-title><source>Int J Mol Sci</source><person-group>
<name><surname>Traboulsi</surname><given-names>H</given-names></name>
<name><surname>Cherian</surname><given-names>M</given-names></name>
<name><surname>Abou Rjeili</surname><given-names>M</given-names></name>
<etal/>
</person-group><fpage>5</fpage><volume>21</volume><year>2020</year></element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>Pulmonary illness related to e-cigarette use in Illinois and Wisconsin &#x02014; final report</article-title><source>N Engl J Med</source><person-group>
<name><surname>Layden</surname><given-names>JE</given-names></name>
<name><surname>Ghinai</surname><given-names>I</given-names></name>
<name><surname>Pray</surname><given-names>I</given-names></name>
<etal/>
</person-group><fpage>903</fpage><lpage>916</lpage><volume>382</volume><year>2020</year><pub-id pub-id-type="pmid">31491072</pub-id>
</element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>Psychiatric disorders and risk for multiple adverse outcomes: a national prospective study</article-title><source>Mol Psychiatry</source><person-group>
<name><surname>Blanco</surname><given-names>C</given-names></name>
<name><surname>Wall</surname><given-names>MM</given-names></name>
<name><surname>Hoertel</surname><given-names>N</given-names></name>
<name><surname>Krueger</surname><given-names>RF</given-names></name>
<name><surname>Liu</surname><given-names>SM</given-names></name>
<name><surname>Grant</surname><given-names>BF</given-names></name>
<name><surname>Olfson</surname><given-names>M</given-names></name>
</person-group><fpage>907</fpage><lpage>916</lpage><volume>26</volume><year>2019</year><pub-id pub-id-type="pmid">31350462</pub-id>
</element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI</article-title><source>N Engl J Med</source><person-group>
<name><surname>Blount</surname><given-names>BC</given-names></name>
<name><surname>Karwowski</surname><given-names>MP</given-names></name>
<name><surname>Shields</surname><given-names>PG</given-names></name>
<etal/>
</person-group><fpage>697</fpage><lpage>705</lpage><volume>382</volume><year>2020</year><pub-id pub-id-type="pmid">31860793</pub-id>
</element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>Imaging of vaping-associated lung disease</article-title><source>N Engl J Med</source><person-group>
<name><surname>Henry</surname><given-names>TS</given-names></name>
<name><surname>Kanne</surname><given-names>JP</given-names></name>
<name><surname>Kligerman</surname><given-names>SJ</given-names></name>
</person-group><fpage>1486</fpage><lpage>1487</lpage><volume>381</volume><year>2019</year><pub-id pub-id-type="pmid">31491070</pub-id>
</element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>Severe pulmonary disease associated with electronic-cigarette-product use - interim guidance</article-title><source>MMWR Morb Mortal Wkly Rep</source><person-group>
<name><surname>Schier</surname><given-names>JG</given-names></name>
<name><surname>Meiman</surname><given-names>JG</given-names></name>
<name><surname>Layden</surname><given-names>J</given-names></name>
<etal/>
</person-group><fpage>787</fpage><lpage>790</lpage><volume>68</volume><year>2019</year><pub-id pub-id-type="pmid">31513561</pub-id>
</element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Vaping-induced acute lung injury</article-title><source>N Engl J Med</source><person-group>
<name><surname>Christiani</surname><given-names>DC</given-names></name>
</person-group><fpage>960</fpage><lpage>962</lpage><volume>382</volume><year>2020</year><pub-id pub-id-type="pmid">31491071</pub-id>
</element-citation></ref><ref id="REF12"><label>12</label><element-citation publication-type="journal"><article-title>Vaping-related acute parenchymal lung injury: a systematic review</article-title><source>Chest</source><person-group>
<name><surname>Jonas</surname><given-names>AM</given-names></name>
<name><surname>Raj</surname><given-names>R</given-names></name>
</person-group><fpage>1555</fpage><lpage>1565</lpage><volume>158</volume><year>2020</year><pub-id pub-id-type="pmid">32442559</pub-id>
</element-citation></ref><ref id="REF13"><label>13</label><element-citation publication-type="journal"><article-title>E-cigarette-/vape-associated lung injury as a cause of interstitial lung disease</article-title><source>Cureus</source><person-group>
<name><surname>Vess</surname><given-names>KB</given-names></name>
<name><surname>Ivan</surname><given-names>N</given-names></name>
<name><surname>Boscia</surname><given-names>J</given-names></name>
</person-group><fpage>0</fpage><volume>16</volume><year>2024</year></element-citation></ref><ref id="REF14"><label>14</label><element-citation publication-type="journal"><article-title>Update: interim guidance for health care providers evaluating and caring for patients with suspected e-cigarette, or vaping, product use associated lung injury &#x02014; United States, October 2019</article-title><source>MMWR Morb Mortal Wkly Rep</source><person-group>
<name><surname>Siegel</surname><given-names>DA</given-names></name>
<name><surname>Jatlaoui</surname><given-names>TC</given-names></name>
<name><surname>Koumans</surname><given-names>EH</given-names></name>
<etal/>
</person-group><fpage>919</fpage><lpage>927</lpage><volume>68</volume><year>2019</year><pub-id pub-id-type="pmid">31633675</pub-id>
</element-citation></ref><ref id="REF15"><label>15</label><element-citation publication-type="journal"><article-title>Diffuse alveolar hemorrhage</article-title><source>Clin Chest Med</source><person-group>
<name><surname>Collard</surname><given-names>HR</given-names></name>
<name><surname>Schwarz</surname><given-names>MI</given-names></name>
</person-group><fpage>583</fpage><lpage>592</lpage><volume>25</volume><year>2004</year><uri xlink:href="https://www.chestmed.theclinics.com/article/S0272-5231(04)00051-6/abstract">https://www.chestmed.theclinics.com/article/S0272-5231(04)00051-6/abstract</uri><pub-id pub-id-type="pmid">15331194</pub-id>
</element-citation></ref><ref id="REF16"><label>16</label><element-citation publication-type="webpage"><article-title>Update: Interim guidance for health care providers for managing patients with suspected e-cigarette, or vaping, product use-associated lung injury &#x02014; United States, November</article-title><date-in-citation content-type="access-date">
<month>11</month>
<year>2024</year>
</date-in-citation><year>2019</year><uri xlink:href="https://www.cdc.gov/mmwr/volumes/68/wr/mm6846e2.htm">https://www.cdc.gov/mmwr/volumes/68/wr/mm6846e2.htm</uri></element-citation></ref></ref-list></back></article>